VIVUS (VVUS) Posts Q3 Loss of 3c/Share

VIVUS (NASDAQ: VVUS) reported Q3 EPS of ($0.10), which may not comapare with the analyst estimate of ($0.25). Revenue for the quarter came in at $33.9 million versus the consensus estimate of $21.9 million.

"While the obesity market develops, we are encouraged by an improving reimbursement environment for Qsymia, increasing net revenue per prescription, and feedback from clinicians who emphasize that our product delivers on the promise of clinically significant weight loss," said Seth H. Z. Fischer, CEO. "Because of its favorable efficacy and safety profile, combined with actual clinical experience since launch, Qsymia is top-of-mind in many conversations taking place about obesity, whether among key healthcare providers, payers, patients or policy makers."

Seth continued: "Additionally, we were pleased to announce in September 2014 the approval by FDA of our supplemental new drug application for STENDRA® (avanafil), making it the only erectile dysfunction medication indicated to be taken as early as approximately 15 minutes before sexual activity."

"Finally, the control of our operating expenses remains a key area of focus, and we continue to make good progress in this regard," Seth added.

For earnings history and earnings-related data on VIVUS (VVUS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49